Research
Hormonal
Semaglutide reduces major adverse cardiovascular events (MACE) by 26% in patients with type 2 diabetes at high cardiovascular risk.
If you have type 2 diabetes and are at high risk for heart problems, semaglutide (Ozempic) is not just for weight loss; it has been proven to reduce the risk of heart attack, stroke, and cardiovascular death by 26%. This makes it a critical tool for protecting your heart health alongside managing your blood sugar.
StrongSupportsHIGH confidence
In the SUSTAIN 6 trial, semaglutide was associated with a 26% reduction in major cardiovascular events [12].
Why this rating
Based on the landmark SUSTAIN 6 trial.
Source
Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
Laura Opalska et al. · Quality in Sport · 2024
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →